Comparison 1.

Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with Alzheimer's disease

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Alzheimer's Disease Assessment Scale ‐ Cognitive subscale (ADAS‐Cog) (least square (LS) mean change from baseline at 6 to 48 months): completers	1	272	Mean Difference (IV, Random, 95% CI)	‐1.81 [‐3.75, 0.13]
2 Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS‐ADL) (LS mean change from baseline at 6 to 48 months): completers	1	280	Mean Difference (IV, Fixed, 95% CI)	3.15 [0.07, 6.23]
3 Deaths (number of deaths over 48 months)	1	304	Risk Ratio (M‐H, Fixed, 95% CI)	0.84 [0.52, 1.34]
4 Serious adverse events (number of participants reporting ≥ 1 serious adverse event over 48 months)	1	304	Risk Ratio (M‐H, Fixed, 95% CI)	0.86 [0.71, 1.05]
5 Neuropsychiatric Inventory (NPI) (LS mean change from baseline at 6 to 48 months): completers	1	280	Mean Difference (IV, Fixed, 95% CI)	‐1.47 [‐4.26, 1.32]
6 Mini‐Mental State Examination (MMSE) (LS mean change from baseline at 6 to 48 months): completers	1	273	Mean Difference (IV, Fixed, 95% CI)	0.19 [‐0.72, 1.10]
7 Adverse events (number of participants reporting ≥ 1 adverse event over 48 months)	1	304	Risk Ratio (M‐H, Fixed, 95% CI)	1.02 [0.85, 1.23]